WHAT IS ALREADY KNOWN ON THIS TOPIC
REMISSION
Discontinuation of certain classes of biological disease-modifying antirheumatic drugs (bDMARDs) following clinical remission can be successful. However, there is also persuasive evidence indicating that discontinuing bDMARDs may eventually result in flares in the majority of patients. Randomised control studies evaluating the discontinuation of targeted synthetic DMARDs are lacking.